25 results about "Buccal use" patented technology

The present disclosure relates to a pouched product for oral use, comprising a filling material and a saliva-permeable pouch enclosing the filling material, wherein the filling material comprises carrier units and an active agent, wherein the carrier units are constituted by wadding carrier units comprising or consisting of wadding fibers. The present disclosure relates to manufacturing wadding carrier units and the present disclosure relates to a method of manufacturing pouched products for oral use.

The name of the invention is a self-film-forming composition for oral care. A self-film-forming composition in powder form, reconstituted formulations and kits for oral use are provided that enable sufficient colonization of probiotics in the oral cavity and sufficient residence time to achieve beneficial effects against pathogens associated with oral conditions. Thus, the provided items are suitable for use in the prevention and / or treatment of conditions associated with alterations in oral microbiota, in particular peri-implantitis. The self-film-forming composition in powder form comprises at least one gelling agent and / or at least one bioadhesive and at least one strain of lactic acid bacteria.

A composition comprising a glucagon-like peptide 1 (GLP-1) agonist for sublingual or buccal administration, wherein the composition comprises one or more agents selected from the group consisting of; sodium glycodeoxycholate; sodium deoxycholate; carboxymethyl cellulose; sodium alginate; SNAC (salcaprozate sodium); a non-ionic ester alkoxylate (or alkanoic acid ester alkoxylate); and soy lecithin.

The disclosure provides an oral product configured for oral use, the oral product including a main body including a composition containing at least one water-soluble component capable of release from the main body when placed in the oral cavity, the main body having an outer surface; and a powder coating adhered to at least a portion of the outer surface of the main body, the powder coating including at least one flavorant or at least one active ingredient or a combination of at least one flavorant and at least one active ingredient. The disclosure also provides a method of forming an oral product, which includes receiving a main body including a composition containing at least one water-soluble component capable of release from the main body, the main body having an outer surface; and applying a powder coating composition to at least a portion of the outer surface.

The disclosure provides a pouched oral product configured for oral use, including a composition enclosed in a water-permeable pouch, wherein one or both of the composition and the water-permeable pouch include at least one humectant. The disclosure also provides a method of forming a pouched oral product configured for oral use, the method including providing a pouched oral product comprising a composition enclosed in a water-permeable pouch, the water-permeable pouch having an outer surface; placing the pouched oral product in a container for sale to a consumer; and applying a liquid composition to the outer surface of the water-permeable pouch to form a treated pouched product, the liquid composition comprising a humectant, wherein the applying occurs before or after placing the pouched oral product in the container.

The invention pertains to a natural chewing gum with nicotine (20) comprising a natural gum base (30) and active substance nicotine (34, 36, 38). The natural gum base (30) includes components or ingredients such as a gum base made of chicle with gum arabic or acacia, heat mixed with nicotine (34, 36, 38) in specific quantities. The chewing gum (20) is designed to administer nicotine during buccal use (70) up to 30 minutes while quickly releasing nicotine substance the first 5 minutes. The gum base (30) is covered with a glazing layer (40) with flavors (42) such as mint, strawberry, and taste enhancers with natural ingredients (44) such as xylitol, stevia, glycerin; beet powder, or spirulina, or a combination. A method for manufacturing the natural chewing gum (20) is disclosed, involving manufacturing of the gum base (100), addition of nicotine (200), manufacturing of the glazing mix (300), a glazing process (400), before packaging (500).

The device comprises an oral structure and a nasal structure, a charging structure is arranged between the oral structure and the nasal structure, the two ends of the oral structure are respectively provided with an opening, a space for air to pass through is arranged between the inner walls of the oral structure, one end of the oral structure is connected with one end of the charging structure, and the other end of the oral structure is connected with the other end of the nasal structure. The other end of the oral structure is held by lips of a user or bitten by teeth of the user, the two ends of the nasal structure are opened respectively, a space for gas to pass through is formed between the inner walls, one end of the nasal structure is connected with the other end of the charging structure, and the other end of the nasal structure is inserted into nostrils of the user. The problem that at present, rhinitis patients are difficult to have a rest due to the rhinitis problem is solved, and the problem that fatigue feelings are difficult to relieve when different people are tired at present is solved; the problem that the body of a user is affected due to the fact that some users adopt a smoking mode for refreshing is also solved; and the requirements of oral cavity use and nasal cavity use modes of different users can be met.

The invention pertains to a natural chewing gum with nicotine (20) comprising a natural gum base (30) and active substance nicotine (34, 36, 38). The natural gum base (30) includes components or ingredients such as a gum base made of chicle with gum arabic or acacia, heat mixed with nicotine (34, 36, 38) in specific quantities. The chewing gum (20) is designed to administer nicotine during buccal use (70) up to 30 minutes while quickly releasing nicotine substance the first 5 minutes. The gum base (30) is covered with a glazing layer (40) with flavors (42) such as mint, strawberry, and taste enhancers with natural ingredients (44) such as xylitol, stevia, glycerin; beet powder, or spirulina, or a combination. A method for manufacturing the natural chewing gum (20) is disclosed, involving manufacturing of the gum base (100), addition of nicotine (200), manufacturing of the glazing mix (300), a glazing process (400), before packaging (500).

Pharmaceutical composition comprising a bilayer mucoadhesive film comprising at least two consecutive interconnected layers and incorporating at least one active agent selected from proteins, nucleic acids and combinations thereof, adapted for buccal administration. Said films for use as a medication, in particular for use in treating viral diseases. A method for preparing said film, comprising the steps: a) preparing a backing layer by spreading a liquid composition comprising a water-insoluble polymer, and allowing to dry at ambient conditions to obtain a dried layer; b) preparing a liquid mucoadhesive mixture containing at least one active agent selected from proteins, nucleic acids, and combinations thereof, pouring the mucoadhesive mixture onto the dried layer from step (a), and allowing to dry at ambient conditions to obtain a dried bilayer film; and c) cutting the dried bilayer film into the desired shape and size.

Described herein are methods for treating one or more skin conditions by administering, via the topical route, a composition comprising substituted or unsubstituted diindolylmethane. In particular, methods are provided for improving the dermal bioavailability and pharmacokinetic parameters of substituted or unsubstituted diindolylmethane following a topical administration, relative to an oral administration or a sublingual or buccal administration.

A composition comprising a glucagon-like peptide 1 (GLP-1) agonist for sublingual or buccal administration, wherein the composition comprises one or more agents selected from the group consisting of; sodium glycodeoxycholate; sodium deoxycholate; carboxymethyl cellulose; sodium alginate; SNAC (salcaprozate sodium); a non-ionic ester alkoxylate (or alkanoic acid ester alkoxylate); and soy lecithin.

The present application provides compositions that are provided within a semi-permeable membrane. The compositions can include a particulate material, such as a cellulose, a sugar alcohol, and nicotine. The composition can provide a fast onset of action of the nicotine in the mouth of a user. In particular, when subjected to an in vitro dissolution test using UV detection, about 30% or more of the total content of the nicotine is released from the composition within 30 minutes.

The present invention relates to a mucoadhesive layer for buccal administration of an active pharmaceutical ingredient (API), and to a method of preparing such mucoadhesive layer. Moreover, the present invention also relates to a mucoadhesive film comprising a mucoadhesive layer for buccal administration of an active pharmaceutical ingredient, and to a method of preparing such mucoadhesive film.

The present disclosure provides pouched products that include an outer water-permeable pouch defining a cavity; and a composition adapted for oral use situated within the cavity, the composition including at least one water-soluble component, a substantially spherical filler component in an amount of about 60% or more by dry weight of the composition, and water in an amount of about 30% or less by weight of the composition, wherein the average particle size of the substantially spherical filler component is about 350 microns to about 650 microns.

A dispersible solid pharmaceutical composition buccal dosage form is provided that results in a better pharmacokinetic profile in conjunction with a reduced incidence of adverse side effects and may be administered under fasting conditions. The buccal dosage form may include misoprostol or a pharmaceutically acceptable salt thereof, one or more disintegrants, lubricants, diluents, and optionally one or more other excipients (including but not limited or antioxidant, color, or flavor). The buccal dosage form may have a hardness of about 6 pK to about 10 pK, allows administration non-orally, namely buccally; disintegration or dispersion in less than about 60 seconds; and has a greater than about 80 percent dissolution at 15 minutes.

The present invention relates to the formulation of innovative pharmaceutical compositions for buccal use for use in the treatment and prevention of mucocutaneous diseases of the oral cavity. Said pharmaceutical compositions are able to resist salivary re-washing and have a high substantivity on the oral mucous membranes, obtaining a massive topical effect with the minimum possible systemic assimilation.

Disclosed are methods of treating substance use disorders with formulations comprising 5-MeO-DMT or a salt thereof. such as by intravenous, intramuscular, or buccal administration. In some embodiments, treatment comprises one or more therapy sessions. Methods further comprise a plurality of treatment steps to aid in the efficacy of treating moderate to severe substance use disorders.

This disclosure provides oral, sublingual or buccal use of P1,P4-diadenosine tetraphosphates as antithrombotic agents in vivo, and in particular as antiplatelet agents for prevention and / or treatment of diseases related to platelet activation and aggregation. The disclosure also provides formulations which enhance the oral, sublingual or buccal bioavailability of the P1,P4-diadenosine tetraphosphates.

Described herein are methods for treating one or more skin conditions by administering, via the topical route, a composition comprising substituted or unsubstituted diindolylmethane. In particular, methods are provided for improving the dermal bioavailability and pharmacokinetic parameters of substituted or unsubstituted diindolylmethane following a topical administration, relative to an oral administration or a sublingual or buccal administration.

The present invention relates to the use of methylcellulose as a humectant in a pouch substrate and to a pouch for oral use comprising a pouch substrate wherein the pouch substrate comprises one or more carriers, one or more active ingredients and methylcellulose having a 5 viscosity at 20 DEG C of from about 200 to about 10000 cP at a concentration of 2% w / v.

Liquid, gel, and semi-solid compositions containing naloxone base, or isomers or derivatives thereof, with one or more non-aqueous solvents, and optional viscosity adjusting agents, are provided. Methods of treating an individual exhibiting symptoms of respiratory depression associated with known or suspected opioid overdose including administering a liquid, gel, or semi-solid formulation containing a solution of naloxone base, or an isomer or a derivative thereof, in one or more non-aqueous solvents, are also provided.

The present invention relates to a macrolide for use in a method of preventing or treating an immune disease or condition, preferably transplant rejection, comprising administering said macrolide at least twice a day wherein said at least twice a day administration comprises administering a first dose at a first point in time and administering a second dose at a second point in time, wherein the second time point is a time point in the range of from about 1 hour to about 7 hours, preferably from about 2 hours to about 5 hours, more preferably from about 2.5 hours to about 3.5 hours, even more preferably from about 3 hours after the first time point. The invention also relates to a tacrolimus mucoadhesive film suitable for buccal administration.

The present invention relates to an article, also referred to as an edible chew, which can be applied to oral use by infants and young children, especially during teething and / or for soothing, as well as to a method of manufacture of this edible chew.

We provide bite blocks, medical structures for protecting teeth. [Solution] The bite block of the present invention comprises a tooth protection member 11 having a perforation and a sleeve 12 provided on the front side of the tooth protection member and communicating with the perforation, wherein the sleeve communicates with the perforation, allowing for the insertion of an endotracheal tube and entry into the user's oral cavity. When in use, the tooth protection member is positioned between the user's upper and lower jaws and is placed in the user's mouth and bitten, preventing the user's teeth from moving or breaking in the event of a reflexive teeth clenching.